entertainment -WSS

entertainment

author：focus 2025-09-28 00:13:37 - browse：5

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

knowledge

WSS

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Devoted Health’s losses in Medicare Advantage persist

Devoted Health’s losses in Medicare Advantage persist

Readout Newsletter: Amgen, Regeneron, BGI Group and more

A protest over insulin prices is seen as a fight for life

Texas Medical Board asked to define abortion emergency exception

entertainment

entertainment

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

340B reform proposal comes out of Senate working group

Medical records are filled with copy

Problems with a popular proposal to regulate AI in health care

Supreme Court strikes down use of affirmative action

Global cancer cases to surge 77% by 2050, WHO report says

Drug repurposing or repositioning? The language matters

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Malaria cases in Florida and Texas: Here’s what you need to know

Problems with a popular proposal to regulate AI in health care

hotspot

Bernie brings in new pharma CEOs to talk drug prices

Childhood cancer progress stalls for Black, Hispanic kids: Report

Texas Medical Board asked to define abortion emergency exception

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Unique patient identifier: Experts argue the benefits, pitfalls

Wikipedia

focus

knowledge

entertainment